Igor Svetlichniy/Shutterstock
Brazil’s federal health regulator Anvisa issued a statement this afternoon informing that it has suspended all import authorizations for androgen receptor antagonist proxalutamide. Studies using the drug are also banned.
Anvisa also decided to launch a probe into “potential sanitary infractions” in documents submitted by importers upon requesting authorization, after identifying suspicions that some of the documents may have been fraudulent.
The decision comes after news website Matinal reported the HBMPA military hospital in the southern Brazilian city of Porto Alegre had administered proxalutamide to roughly 50 Covid-19 patients in March, despite lacking regulatory approval for clinical trials.
In June, Brazil’s far-right President Jair Bolsonaro lauded proxalutamide as the “new chloroquine” — a reference to the antimalarial drug the president touted as a “potential miracle cure” for Covid-19, despite a dearth of scientific evidence as to its efficacy.
The accounts of federal, state, and municipal governments, plus those of state-owned companies, recorded a…
The intense floods that chastise Rio Grande do Sul, Brazil’s southernmost state, have killed over…
Brazil's southernmost state of Rio Grande do Sul, a state the size of Ecuador, has…
In September 2023, an extratropical cyclone hit Brazil’s South region, causing heavy rains and floods…
The Abu Dhabi National Oil Company (ADNOC) is no longer interested in buying Novonor's controlling…
Brazilian railway operator Rumo announced a partial interruption of its activities in southern Brazil on…